Editorial: Genetics of Barrett's: The Bigger, the Better

El-Omar, Emad; Jankowski, Janusz

doi:10.1038/ajg.2012.144

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The probability to find one single specific biomarker providing all diagnostic, predictive, and prognostic significance in GERD, BE, and/or EAC is rather utopian, and a panel of biomarkers maybe will solve this problem [81, 123, 124]. Upcoming new technologies such as RNA and DNA microarrays, epigenetics, and proteomics in association with bioinformatics give hope to find novel and reliable biomarkers in gastrointestinal tumors and especially for prognosis and prediction of BE and EAC [114].…”

Section: Approach and Outlookmentioning

confidence: 99%

GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

Illig

Klieser

Kiesslich

et al. 2013

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Due to unfavorable lifestyle habits (unhealthy diet and tobacco abuse) the incidence of gastroesophageal reflux disease (GERD) in western countries is increasing. The GERD-Barrett-Adenocarcinoma sequence currently lacks well-defined diagnostic, progressive, predictive, and prognostic biomarkers (i) providing an appropriate screening method identifying the presence of the disease, (ii) estimating the risk of evolving cancer, that is, the progression from Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC), (iii) predicting the response to therapy, and (iv) indicating an overall survival—prognosis for EAC patients. Based on histomorphological findings, detailed screening and therapeutic guidelines have been elaborated, although epidemiological studies could not support the postulated increasing progression rates of GERD to BE and EAC. Additionally, proposed predictive and prognostic markers are rather heterogeneous by nature, lack substantial proofs, and currently do not allow stratification of GERD patients for progression, outcome, and therapeutic effectiveness in clinical practice. The aim of this paper is to discuss the current knowledge regarding the GERD-BE-EAC sequence mainly focusing on the disputable and ambiguous status of proposed biomarkers to identify promising and reliable markers in order to provide more detailed insights into pathophysiological mechanisms and thus to improve prognostic and predictive therapeutic approaches.

show abstract

Section: Approach and Outlookmentioning

confidence: 99%

GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

Illig

Klieser

Kiesslich

et al. 2013

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…8 One study demonstrated basal acid output increased by a median of 96 per cent two days after ranitidine therapy ceased (p<0.01), which returned to pretreatment values by day 10 in healthy volunteers. 9 Other evidence points to a more prolonged effect with longer exposure -at least two months after a two-month treatment course. 8 Data is relatively conflicting with regards to the exact clinical consequences RAHS has from PPIs.…”

Section: Rebound Acid Hypersecretionmentioning

confidence: 99%